Billionaire Steve Cohen Owns Shares of This Stock That Has Soared 1,600% in The Past Year [Yahoo! Finance]
Abivax SA (ABVX)
Company Research
Source: Yahoo! Finance
Investing in clinical-stage biotechs generally offers significant upside potential, along with a healthy, above-average dose of risk. Picking the right ones to put your hard-earned money into while avoiding wealth destroyers can be complicated. It might be worth considering some of the ones that prominent figures on Wall Street are investing in. Take Steve Cohen, the billionaire founder and CEO of Point72 Asset Management, a hedge fund that has delivered outstanding returns over the long run. Point72 Asset Management owns shares of Abivax (NASDAQ: ABVX) , a France-based clinical-stage biotech, whose shares have skyrocketed by more than 1,600% over the trailing 12 months. Is this a great stock for investors to buy? Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Image source: Getty Images. How to invest in r
Show less
Read more
Impact Snapshot
Event Time:
ABVX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABVX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABVX alerts
High impacting Abivax SA news events
Weekly update
A roundup of the hottest topics
ABVX
News
- Abivax (ABVX) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating and a $160.00 price target on the stock.MarketBeat
- 2 Reasons Abivax Stock Could 10X by 2036 [Yahoo! Finance]Yahoo! Finance
- Abivax (ABVX) had its "buy" rating reaffirmed by BTIG Research. They now have a $150.00 price target on the stock.MarketBeat
- Abivax (NASDAQ:ABVX) is now covered by analysts at Wedbush. They set an "underperform" rating on the stock.MarketBeat
- Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026GlobeNewswire